MYOM2 and AL amyloidosis: In 2009, the IMWG recommended sFLC instead of UPE in the MM screening algorithm, but the quantification of M-protein in 24-h urine remains a recommendation in the follow-up of patients with disease that is not measurable by SPE, as a criterion for the response to treatment in both MM and AL amyloidosis [14].